Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts [0.03%]
高白血病细胞计数的急性髓系白血病老年患者的经济评价
D Coyle,Pierre J A Villeneuve
D Coyle
Background: Azacitidine is an hypomethylating agent widely adopted for the treatment of acute myeloid leukaemia (AML) in patients who are ineligible for curative-intent chemotherapy. Patients with low bone marrow blast co...
Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands [0.03%]
荷兰二甲双胍缓释制剂治疗2型糖尿病的预算影响分析
Judith J Gout-Zwart,Lisa A de Jong,Lisanne Saptenno et al.
Judith J Gout-Zwart et al.
Background: Adverse drug reactions and medication nonadherence are well-known causes of sub-optimal disease control and worsened disease outcomes in patients who are treated for type 2 diabetes. Metformin sustained releas...
Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines [0.03%]
爱尔兰的药物卫生技术评估：时间线分析
Emma Connolly,Helen O&#x;Donnell,Felicity Lamrock et al.
Emma Connolly et al.
Background: The National Centre for Pharmacoeconomics (NCPE) is commissioned by the Corporate Pharmaceutical Unit of the Health Service Executive (HSE-CPU) to assess the evidence for the comparative effectiveness and cost...
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong [0.03%]
基于PD-L1的“检测与治疗”策略在港应用派姆单抗治疗转移性非小细胞肺癌的成本效益分析
Herbert H Loong,Carlos K H Wong,Linda Kam Suet Leung et al.
Herbert H Loong et al.
Background: Pembrolizumab, a monoclonal antibody against programmed death ligand 1 (PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non-small-cell lung cancer (NSCLC) with a PD-L1...
Cost of Delivering Secondary Healthcare Through the Public Sector in India [0.03%]
印度通过公共部门提供二级医疗保健的成本
Shankar Prinja,Akashdeep Singh Chauhan,Pankaj Bahuguna et al.
Shankar Prinja et al.
Background: Government spending on provision of secondary healthcare has increased four-fold (in real terms) over the last decade in India. The evidence on the cost of secondary care to the health system is limited. The p...
Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer in a Mexican Population: A Chart Review [0.03%]
墨西哥四期非小细胞肺癌患者的治疗模式和费用：病历回顾分析
Jorge Arturo Alatorre,Saúl Campos-Gómez,Emmanuel De la Mora et al.
Jorge Arturo Alatorre et al.
Background: The available evidence regarding the clinical characteristics, treatment patterns, adverse events (AEs), and costs of treating patients with stage IV non-small cell lung cancer (NSCLC) in Mexico is scarce. ...
Economic Evaluations of Pharmacological Treatments in Heart Failure Patients: A Methodological Review with a Focus on Key Model Drivers [0.03%]
心力衰竭患者药物治疗的经济评价：以关键模型驱动因素为重点的方法学综述
Gian Luca Di Tanna,Shuxian Chen,Anna Bychenkova et al.
Gian Luca Di Tanna et al.
Various decision analytic models exist for evaluating the cost-effectiveness of pharmacological interventions for heart failure (HF). Despite this, studies that explore drivers influencing these modeling approaches remain scarce. Through a ...
Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review [0.03%]
慢性乙型肝炎发表的卫生经济学模型是否适当纳入了e抗原血清学转换带来的获益？系统文献回顾
Peter Wigfield,Urbano Sbarigia,Mahmoud Hashim et al.
Peter Wigfield et al.
Objectives: Sustained hepatitis B surface antigen (HBsAg) loss or 'functional cure' (FC) is considered an optimal treatment endpoint by international clinical guidelines for chronic hepatitis B (CHB), yet rarely is this a...
Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana [0.03%]
早期经济评估以确定新的伤寒检测在冈比亚具有成本效益所必须的测试特征
Samuel N Frempong,Andrew J Sutton,Clare Davenport et al.
Samuel N Frempong et al.
Background: In Ghana, there are issues with the diagnosis of typhoid fever; these include delays in diagnosis, concerns about the accuracy of current tests, and lack of availability. These issues highlight the need for th...
Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India [0.03%]
临床药学干预对印度慢性阻塞性肺疾病患者医药费用的影响研究
Suhaj Abdulsalim,Mazhuvancherry Kesavan Unnikrishnan,Mohan K Manu et al.
Suhaj Abdulsalim et al.
Background: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality, especially in low- and middle-income countries (LMICs) such as India. Medicine costs are a key issue in LMICs, with typ...